Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.30 and traded as low as $6.17. Champions Oncology shares last traded at $6.23, with a volume of 3,932 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Champions Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Champions Oncology Stock Performance

The firm has a market cap of $86.53 million, a P/E ratio of -38.94 and a beta of 0.41. The company’s 50 day moving average is $6.04 and its 200 day moving average is $6.30.

Institutional Trading of Champions Oncology

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 6,229 shares during the last quarter. Mink Brook Asset Management LLC acquired a new position in Champions Oncology in the 4th quarter valued at approximately $555,000. Acadian Asset Management LLC raised its stake in shares of Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 8,814 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Champions Oncology during the first quarter valued at $201,000. Finally, Jane Street Group LLC acquired a new position in shares of Champions Oncology during the first quarter worth $200,000. 41.30% of the stock is owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.